RCUS
USDArcus Biosciences Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$19.700
高値
$20.500
安値
$19.691
出来高
0.41M
企業ファンダメンタルズ
時価総額
2.4B
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
1.18M
取引所
NYQ
通貨
USD
52週レンジ
関連ニュース
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing
関連株式
PET
Wag! Group Co.
FGBIP
First Guaranty Bancshares Inc. 6.75% Series A Fixed-Rate Non-Cumulative Perpetual Preferred Stock
CEE
The Central and Eastern Europe Fund Inc. (The)
WTS
Watts Water Technologies Inc.
CHY
Calamos Convertible and High Income Fund
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。